Agreement - October 9, 2018
InfiCure collaborates with CSL
The Umeå based company InfiCure Bio has signed a contract for global collaboration with the global biotech company CSL. The two companies will test CSL’s experimental anti-fibrotic reagent in the N-IF mouse, InfiCure’s model for fibrosis. The management team of InfiCure Bio believes that the N-IF mouse will become an important player in the field […]
Agreement - October 5, 2018
Novo Nordisk enters digital health partnership
In order to support the future integration of the company’s connected insulin pens, NovoPen 6 and NovoPen Echo Plus, which will become commercially available early 2019 across key markets, Novo Nordisk has signed new partnership agreements with Dexcom, Glooko and Roche. Building upon its existing work with IBM Watson Health and Glooko, Novo Nordisk aims […]
Agreement - October 1, 2018
LEO Pharma enters strategic alliance
LEO Pharma and MorphoSys AG have announced an expansion of their existing strategic alliance to include peptide-derived therapeutics. The objective of the alliance is to identify novel, peptide-derived therapeutics for unmet medical needs that will be valuable additions to both companies’ pipelines. This alliance expands the existing partnership of the two companies signed in November […]
Agreement - September 18, 2018
Moberg Pharma enters licensing deal
The company has signed an exclusive license agreement with Cipher Pharmaceuticals for MOB-015 in Canada. Cipher will commercialize MOB-015 in Canada upon completed phase 3 studies and registration. Under the agreement, Moberg Pharma is eligible to receive USD 14.6 million in one-time payments and milestones, as well as royalties on net sales in Canada. Moberg Pharma […]
Agreement - September 6, 2018
Pelago and Vertex enter collaboration and license agreement
Pelago Bioscience and Vertex Pharmaceuticals have entered into a 2-year strategic research collaboration and license agreement. During the collaboration, the companies will together develop assay expertise in all CETSA formats and will also generate data to determine the value of implementing CETSA widely across Vertex’s drug discovery pipeline. “This collaboration will allow us to explore […]
Agreement - August 2, 2018
Bonesupport in agreement with MTF Biologics
The company has signed an agreement with MTF Biologics, the world’s largest tissue bank, to extend and strengthen its US product offering. The agreement will give the company US rights to two forms of bone graft materials comprised of 100% demineralized bone matrix (DBM), which offer improved osteoinductivity when compared to many other DBM products […]
